- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company foc ...

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating G1 Therapeutics, Inc. (Nasdaq: GTHX), relating to its proposed merger with Kahn Swick & Foti, LLC (“KSF”). Under the terms of the proposal, KSF will commence a tender offer to purchase GT ...

产品上市和商业化 - 公司于2021年2月获得FDA批准上市COSELA®(trilaciclib)，这是首个也是唯一一个用于预防化疗引起骨髓抑制的治疗药物[138] - COSELA在中国大陆、香港、澳门和台湾地区也获得上市批准，由合作伙伴先声制药负责商业化[139] - 公司正在评估COSELA在其他骨髓保护适应症的使用，包括与lurbinectedin联合使用，并寻找合作伙伴开发COSELA与主要ADC疗法的联合用药[143] 临床试验结果 - 公司于2024年6月宣布了PRESERVE 2期III期试验的最终结果，未能在转移性三阴性乳腺癌患者群体中达到统计学显著疗效[145] 许可和合作 - 公司已与Pepper Bio和Deimos Biosciences分别就lerociclib在全球范围内(除亚太地区)的开发和商业化达成独家许可协议[147] - 公司通过COSELA的全球商业化、营销和分销安排、战略联盟和许可安排等方式获得资金[200,201] - 公司已与Pepper和Deimos签署了lerociclib的独家许可协议[192] 财务表现 - 公司于2024年上半年实现了2.99亿美元的COSELA销售收入和1.1亿美元的许可收入[149,154] - 截至2024年6月30日,公司拥有1.51亿美元的现金及现金等价物和4.57亿美元的可供出售证券[150] - 产品销售净额同比增长43%，达到1,583.8万美元[169] - 许可收入同比下降98%，至70万美元[170] - 研发费用同比下降52%，至573.8万美元[172] - 销售、一般及管理费用同比下降22%，至1,361.0万美元[173] - 其他费用净额同比增加29%，至193.4万美元[174] - 产品销售净额同比增长39%，达到2,991.7万美元[178] - 许可收入同比下降97%，至110.5万美元[179] - 销售成本同比下降37%，至181.2万美元[180] - 研发费用同比下降53%，至1,305.6万美元[181] - 销售、一般及管理费用同比下降27%，主要是人员成本、商业化活动、与trilaciclib相关的医疗事务费用以及审计、法律、IT、税务、办公和其他行政费用的减少[182] - 其他费用净额同比下降7%，主要是由于贷款利息费用减少1.1百万美元,部分被利息收入减少0.9百万美元所抵消[183] - 所得税费用同比下降1.3百万美元,主要是由于上期支付Simcere的一次性特许权使用费导致的外国预提税费用[184] 现金流和资金需求 - 公司预计现有现金及现金等价物和有价证券足以支持未来至少12个月的计划运营,并符合贷款协议中的财务约定[201] - 公司需遵守最低现金余额和有条件借款基础的要求,如不符合可能会被贷款人要求立即偿还贷款[191] - 公司经营活动现金流出同比减少796,000美元,投资活动现金流入同比增加2,262,000美元,融资活动现金流出同比减少18,478,000美元[193] - 公司预计通过成功商业化COSELA、营销和分销安排以及其他合作、战略联盟和许可安排来满足现金需求[204] - 除了在许可安排和与Hercules的贷款协议项下包含的金额外,公司没有任何承诺的外部资金来源[204] - 公司可能受到与Hercules贷款协议下的持续财务契约合规性的约束[204] - 如果公司通过出售股权或可转换债务证券筹集额外资本,股东的所有权权益将被稀释,这些证券的条款可能包括清算或其他优先权,这可能会不利影响普通股东的权利[204] - 如果公司无法在需要时筹集到额外资金,可能被要求推迟、限制、减少或终止产品开发或未来商业化努力,或授予开发和营销产品候选药的权利[204] 其他财务信息 - 公司在当前期间的合同义务没有发生重大变化[205] - 公司在列报期内没有任何资产负债表外安排[206] - 公司的关键会计政策和重大判断及估计与2023年年报一致[207][208] - 公司在本季度未采用对其财务状况和经营业绩有重大影响的新会计准则[209] - 公司面临利率风险,但利息收入波动历来不大,利率变化不会对其业务、财务状况或经营业绩产生重大影响[210] - 公司的贷款协议利率存在可变性风险,截至2024年6月30日未偿还本金为41.8百万美元[211] - 公司目前未面临重大的外汇风险,但未来可能受到汇率波动的影响[212] - 通胀主要影响公司的劳动力成本,但在2024年上半年未对公司业务、财务状况或经营业绩产生重大影响[213]

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 41.18%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.20, delivering a surprise of -5.26%.Over the last four quarters, the company has surp ...

MILWAUKEE, Aug. 7, 2024 /PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with Pharmacosmos.Click here to learn how to join our investigation https://www.ademilaw.com/case/g1-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.GI shareholders will receive only $7.15 per share in cash for a total equity value of approximately $405 million. The transaction agreemen ...

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for ...

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1’s COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos’ Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos’ Global Commercial Portfolio - - G1’s Shareholders to Receive U.S. $7.15 per Share in Cash for ...

RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes p ...

While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ:GTHX) appears quite enticing. First and foremost, it levers acumen in the burgeoning small-molecule therapeutics space. Second, G1 Therapeutics stock seems undervalued for what speculators may be getting.Of course, to make the case that GTHX is a bullish idea, an investor must make two critical assumptio ...

Biotechnology stocks can be thrilling and profitable when you’re on the winning side of a trade. G1 Therapeutics’ (NASDAQ:GTHX) started hot, but then the bottom fell out after an unfortunate announcement. With that in mind, G1 Therapeutics stock is just too risky to recommend right now.Based in North Carolina, G1 Therapeutics specializes in oncology (cancer) treatments. To be fair and balanced, I’ll start off with some positive news pertaining to G1 Therapeutics. Then, however, I’ll have to release a bombsh ...